^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

CINelim (terameprocol)

i
Other names: EM-1421, Tetra-O-Methyl Nordihydroguaiaretic Acid, M4N
Associations
Trials
Company:
Erimos Pharma
Drug class:
Survivin inhibitor, CDK1 inhibitor, Sp1 inhibitor
Associations
Trials
12ms
Tetra-O-methyl-nordihydroguaiaretic acid inhibits energy metabolism and synergistically induces anticancer effects with temozolomide on LN229 glioblastoma tumors implanted in mice while preventing obesity in normal mice that consume high-fat diets. (PubMed, PLoS One)
Tetra-O-methyl-nordihydroguaiaretic acid (terameprocol; M4N), a global transcription inhibitor, in combination with a second anticancer drug induces strong tumoricidal activity and has the ability to suppress energy metabolism in cultured cancer cells...Meanwhile, the ability of M4N to suppress energy metabolism prevented obesity in mice consuming HF diets, indicating that M4N has beneficial effects on normal tissues. The dual ability of combination treatment with M4N to suppress both energy metabolism and oncometabolites shows that it is potentially an effective therapy for cancer.
Preclinical • Journal
|
LDHA (Lactate dehydrogenase A) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • ATF4 (Activating Transcription Factor 4) • NAMPT (Nicotinamide Phosphoribosyltransferase) • TCF4 (Transcription Factor 4)
|
temozolomide • CINelim (terameprocol) • terameprocol oral (EM-1421 oral)